In vitro evidence of complement activation in transplantation-associated thrombotic microangiopathy.

Transplantation-associated thrombotic microangiopathy is associated with complement activation in vitro.This data further supports the use of eculizumab for the treatment of patients with TA-TMA.

[1]  S. Davies,et al.  ST2 and Endothelial Injury as a Link between GVHD and Microangiopathy. , 2017, The New England journal of medicine.

[2]  R. Brodsky,et al.  Transplant-associated thrombotic microangiopathy: opening Pandora’s box , 2017, Bone Marrow Transplantation.

[3]  K. Blakemore,et al.  Direct evidence of complement activation in HELLP syndrome: A link to atypical hemolytic uremic syndrome. , 2016, Experimental hematology.

[4]  K. Myers,et al.  New approaches in the diagnosis, pathophysiology, and treatment of pediatric hematopoietic stem cell transplantation-associated thrombotic microangiopathy. , 2016, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[5]  Ranjit S. Chima,et al.  Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[6]  F. Zou,et al.  The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy. , 2015, Blood.

[7]  Xuan Yuan,et al.  Modified Ham test for atypical hemolytic uremic syndrome. , 2015, Blood.

[8]  B. Dixon,et al.  A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury. , 2015, Blood reviews.

[9]  Francesco Tedesco,et al.  Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. , 2014, Blood.

[10]  Ranjit S. Chima,et al.  Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. , 2014, Blood.

[11]  S. Davies,et al.  Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy. , 2011, Blood.

[12]  C. Thoburn,et al.  Glycosylphosphatidylinositol-anchored protein deficiency confers resistance to apoptosis in PNH. , 2009, Experimental hematology.

[13]  J. George.  Hematopoietic stem cell transplantation-associated thrombotic microangiopathy: defining a disorder , 2008, Bone Marrow Transplantation.

[14]  H. Lazarus,et al.  Diagnosis and treatment of transplantation-associated thrombotic microangiopathy: real progress or are we still waiting? , 2007, Bone Marrow Transplantation.

[15]  K. McCoy,et al.  The Biochemical and Cellular Basis of Cell Proliferation Assays That Use Tetrazolium Salts , 1996 .

[16]  L. Leive,et al.  Complement activation via the alternative pathway by purified Salmonella lipopolysaccharide is affected by its structure but not its O-antigen length. , 1984, Journal of immunology.

[17]  L. Kline,et al.  Activation of the classical and properdin pathways of complement by bacterial lipopolysaccharides (LPS). , 1977, Journal of immunology.